Genomics of Drug Sensitivity in Cancer |
Refametinib
|
Synonyms |
RDEA119, BAY-86-9766, BAY 869766
|
Targets |
MEK1, MEK2
|
Target pathway |
ERK MAPK signaling
|
PubCHEM ID |
44182295
|
Jsmol |
|
Download molecule |
44182295
|
PUBCHEM IUPAC INCHI |
InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1
|
Smiles |
IC3(=CC(F)=C(NC1(=C(F)C(F)=CC(=C1NS(=O)(=O)C2(CC2)(CC(O)CO))OC))C=C3)
|
Cluster number |
3
|
calculated LogS |
-6,587
|
Molecular weight |
572,337
|
calculated LogP |
3,0278
|
H-Acceptors |
7
|
H-Donors |
4
|
Ro5 violations |
1
|
Druglikeness |
-2,5979
|
DrugScore |
6,84758161728631E-02
|
Mutagenic |
high
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
high
|
Fish Toxicity |
High FHMT
|
Fish Toxicity2 |
1,293
|
Rat Acute Toxicity |
2,4748
|
Acute Oral Toxicity |
III
|
Caco-2 Permeability |
Caco2-
|
Caco-2 Permeability2 |
0,3586
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Inhibitor
|
P-glycoprotein Inhibitor2 |
Non-inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition2 |
Inhibitor
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity2 |
0,4399
|
AMES Toxicity |
Non AMES toxic
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 3A4 Inhibitor |
Inhibitor
|
CYP450 2C19 Inhibitor |
Inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 1A2 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Substrate |
Non-substrate
|
Biodegradation |
Not ready biodegradable
|
Carcinogenicity (Three-class) |
Non-carcinogens
|
Carcinogens |
Non-required
|
Blood-Brain Barrier |
BBB-
|
CYP Inhibitory Promiscuity |
High CYP Inhibitory Promiscuity
|
Honey Bee Toxicity |
Low HBT
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Subcellular localization |
Mitochondria
|
Human Intestinal Absorption |
HIA+
|
Aqueous solubility |
-4,0096
|